The stock market experienced a serious bout of volatility last week, which may have opened up some buying opportunities.
When the market is volatile, it is crucial to make sure your stock selection is watertight. The stocks below have 100% buy ratings from analysts and top analysts alike. You can draw confidence from the fact that the stocks have the support of these best-performing analysts who consistently get it right.
To find these 'Strong Buy' stocks, we turned to TipRanks' stock screener. This allowed us to pull up only stocks with very bullish Street sentiment. We scanned for stocks with 1) only buy ratings and 2) big upside potential. From the results, the following five stocks easily stood out from the crowd.
Iovance Biotherapeutics (IOVA)
- 6 buy ratings in the last three months.
- 32% upside potential from current share price.
This innovative anti-cancer company has just released encouraging preliminary data from two ongoing trials. Analysts have responded quickly with a slew of buy ratings and price target increases over the last 10 days. One of these analysts is Oppenheimer's Mark Breidenbach. We can see that he boasts an incredible track record on Iovance stock, specifically with a 100% success rate and 112% average return.
He explains that the Phase 2 trial results for LN-145 revealed a 50% objective response rate (ORR) in two cervical cancer patients and a 38% ORR in eight (SCCHN) patients with carcinoma of the head and neck (SCCHN). Investors should now keep an eye out for interim readouts from three ongoing trials that could significantly de-risk Iovance's entire pipeline over the next 12-18 months.
"Based on these encouraging preliminary data and the company's increased operational freedom to develop LN-144 and LN-145 TIL products, we reiterate our Outperform rating and raise our price target to $19" says Breidenbach.
- 22 buy ratings in the last three months.
- 30% upside potential from current share price.
Semiconductor king Broadcom, which is a holding in Action Alerts Plus, consistently has one of the best outlooks on the Street. Indeed, Broadcom has received only buy ratings and rising price targets for over 8 months now. Most recently, one of the Street's top analysts, B.Riley FBR's Craig Ellis ramped up his Broadcom price target from $330 to $335 (35% upside).
His move comes on the back of a 'truly surprising' guidance announcement from Broadcom. On Jan 31, the company raised its quarterly outlook above the Street while also initiating an above-Street fiscal year sales view. Shares soared 3% on the news, while six analysts reiterated their bullish Broadcom calls.
According to Ellis, this guide-up supports his long-held assertion that "under-appreciated pent-up demand positives exist." He notes that while weak smartphone data points are dominating headlines, other material upside drivers have emerged. The result: a more balanced and healthy overall environment for Broadcom. Ellis concludes: "We believe positive EPS revision catalysts can persist for the attractively valued shares which trade at a compelling 12.4x and 11.5x our F18 and F19 EPS."
Energy Transfer Partners (ETP)
- 6 buy ratings in the last three months.
- 26% upside from the current share price.
Dallas-based Energy Transfer Partners is a Fortune 500 natural gas and propane company. The company boasts over 71,000 miles of pipelines that spread across 38 states. Top RBC Capital's Elvira Scotto reiterated her Energy Transfer Partners buy rating on January 16. She sees the stock spiking to $24 (22% upside potential). According to Scotto, the company should continue to benefit from growing crude oil production in the US. She is also confident that the company's expansion opportunities (including re-purposing existing assets) should drive attractive returns.
Our data reveals that Scotto is ranked #31 out of over 4,700 tracked analysts. She scores a 72% success rate and 26% average return over her 254 ratings.
- 17 buy ratings in the last three months.
- 10% upside potential from current share price.
Now is a good time to invest in Chinese e-commerce giant Alibaba, say top analysts. The company has just released unexpectedly mixed results. Revenue jumped by a massive 56% from the third quarter to $12.76 billion. However, earnings of $1.63 a share missed consensus estimates by $0.04, causing shares to drop almost 6%.
But this has not deterred the Street. Analysts, including Stifel Nicolaus' Scott Devitt, are clear that any pullback in shares should be treated as a buying opportunity. Devitt points out strong active customer growth, soaring revenues and the impressive 104% growth for cloud services compared to last year.
- 6 buy ratings in last three months.
- 34% upside potential from current share price.
BioMarin develops and commercializes treatments for rare genetic diseases with serious unmet need. For top JP Morgan analyst Cory Kasmiov, its full steam ahead. He says: "BioMarin continues to be one of our top picks for 2018 with shares positioned to emerge from ~2 years of stagnation between a new product cycle and key pivotal readouts ahead."
Specifically, investors can look forward to pegvaliase for the genetic condition PKU, vosoritide for the most common form of human dwarfism (achondroplasia) and a gene therapy platform expected at the end of this quarter. Kasmiov reiterated his BioMarin buy rating on January 24, with a bullish $129 price target (43% upside potential).
Startled by Friday's big plunge in the stock market? TheStreet's newsroom discusses what could happen next.
Subscribe on Youtube for extended interviews, Cramer Replays, feature content, and more!
More of What's Trending on TheStreet:
- Will Super Bowl Beer Sales Be Enough to Keep Old School Brewers Afloat?
- How to Use Credit Card Debt to Your Advantage if You're Under 30
- Will My Spouse's Social Security Be Cut by the Windfall Elimination Provision?
- The Best Jobs in America